Literature DB >> 15232291

N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats.

Rita Krishnamurthi1, Simon Stott, Matt Maingay, Richard L M Faull, Dianne McCarthy, P Gluckman, J Guan.   

Abstract

Central administration of N-terminal tripeptide of IGF-1 (GPE) prevents the loss of dopamine neurons. We now examine effects of GPE administered peripherally, on long-term functional recovery after 6-OHDA lesion in rats. GPE treatment (3 mg/kg, i.p.), 3 days after the lesion reduced the number of rotations (p<0.005) and the time over meter (p<0.005) compared to vehicle treatment. Step length and number of adjusting steps were increased in the GPE group (p<0.005), particularly at 12 weeks post lesion. However, GPE treatment did not prevent the loss of tyrosine hydroxylase in the substantia nigra pars compacta and the striatum. The study suggests that peripheral administration of GPE after onset of nigrostriatal dopamine depletion improves long-term Parkinsonian motor deficits, independent of neuronal outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232291     DOI: 10.1097/01.wnr.0000127461.15985.07

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  13 in total

1.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

Review 2.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

3.  IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.

Authors:  Amina El Ayadi; Michael J Zigmond; Amanda D Smith
Journal:  Exp Brain Res       Date:  2016-02-19       Impact factor: 1.972

4.  Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.

Authors:  Li Xu; Wen-Fang Chen; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

Review 5.  IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.

Authors:  Jian Guan; Peter D Gluckman
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

Review 6.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017

7.  A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats.

Authors:  R V M Krishnamurthi; S Mathai; A H Kim; R Zhang; J Guan
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

Review 8.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

9.  Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence.

Authors:  Dimitrios Adamis; David Meagher
Journal:  J Aging Res       Date:  2011-07-03

10.  Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease.

Authors:  Deniz Tuncel; Fatma Inanc Tolun; Ismail Toru
Journal:  Mediators Inflamm       Date:  2009-03-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.